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Background-—Using data from the GARFIELD-AF (Global Anticoagulant Registry in the FIELD–Atrial Fibrillation), we evaluated the
impact of chronic kidney disease (CKD) stage on clinical outcomes in patients with newly diagnosed atrial ﬁbrillation (AF).
Methods and Results-—GARFIELD-AF is a prospective registry of patients from 35 countries, including patients from Asia (China,
India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013–2016) were classiﬁed with no, mild, or
moderate-to-severe CKD, based on the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative guidelines. Data on
CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had
moderate-to-severe CKD, 16.9% (n=5595) mild CKD, and 72.1% (n=23 816) no CKD. The use of oral anticoagulants was inﬂuenced by
stroke risk (ie, post hoc assessment of CHA2DS2-VASc score), but not by CKD stage. The quality of anticoagulant control with vitamin K
antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, bothmild andmoderate-
to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a
higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure.
The impact ofmoderate-to-severe CKD onmortality was signiﬁcantly greater in patients fromAsia than the rest of the world (P=0.001).
Conclusions-—In GARFIELD-AF,moderate-to-severe CKDwas independently associatedwith stroke/systemic embolism,major bleeding,
and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01090362. ( J Am Heart Assoc. 2019;8:
e010510. DOI: 10.1161/JAHA.118.010510.)
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E pidemiologic studies suggested the increased preva-lence of atrial ﬁbrillation (AF) in patients with chronic
kidney diseases (CKDs).1,2 Indeed, the prevalence of both AF
and CKD increases with age and concomitant risk factors.3–7
Moreover, there are several common risk factors for high
prevalence of AF and CKD such as hypertension, diabetes
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mellitus, and obesity.4–6 Thus, the number of patients with
concomitant AF and CKD increases as the population ages.
From a clinical outcomes perspective, comorbid CKD is
an independent predictor of stroke and bleeding events in
patients with AF.8,9 Risk of stroke and hemorrhage in this
patient group increases progressively with declining renal
function.10 Thus, the HAS-BLED (hypertension, abnormal
renal or liver function, stroke, bleeding, labile international
normalized ratio, elderly, drugs predisposing to bleeding or
history of alcohol abuse) score, which was designed to
predict the bleeding risk of patients with AF, includes “L” for
liver or kidney dysfunction. The HAS-BLED score was
developed in 2010 using the Euro Heart Survey database.11
Similarly, high rates of stroke and an increased risk of
bleeding were also shown in a 2012 Danish cohort study of
patients with AF and concomitant CKD.9 Subsequently, a
series of observational studies of patients treated mainly
with vitamin K antagonists (VKAs), have shown equivocal
and conﬂicting evidence of the value of anticoagulation for
stroke prevention in patients with comorbid CKD and AF.12–
18 These data highlight the difﬁculties in maintaining optimal
anticoagulation control with VKAs in patients with CKD.12–18
A better understanding of the impact of CKD on outcomes
among patients with AF in the contemporary treatment
setting is needed, assessing the impact of CKD and the
experience with anticoagulants beyond Western Europe and
North America.
The GARFIELD-AF (Global Anticoagulant Registry in the
FIELD–Atrial Fibrillation) is an ongoing, international, prospec-
tive registry of newly diagnosed patients with AF at risk of
stroke. We aimed to clarify the relationship between CKD stage
and clinical outcomes—reﬂecting real-world clinical practice
during an era when non-VKA oral anticoagulants (NOACs) are
available. Using global data from this noninterventional registry,
we attempted to conﬁrm the hypothesis that CKD stage
inﬂuences clinical outcomes among a highly diverse group of
newly diagnosed patients with AF. In addition, we aimed to
clarify the impact of CKD on clinical outcomes in Asia, where
both the clinical characteristics of patients as well as the
standard of care with antithrombotic therapy differ from the
rest of the world (RoW).19
Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Study Design and Participants
The study design of GARFIELD-AF has been described
previously.20 Brieﬂy, GARFIELD-AF is a contemporary,
international, and sequentially recruited cohort of patients
with newly diagnosed AF at risk of stroke. Men and women
aged ≥18 years with nonvalvular AF diagnosed according to
standard local procedures within the previous 6 weeks, and
with at least 1 risk factor for stroke as judged by the
investigator, are eligible for inclusion. Risk factors for
stroke were not prespeciﬁed in the protocol, nor are they
limited to the components of existing risk stratiﬁcation
schemes such as CHA2DS2-VASc score. Patients with a
transient reversible cause of AF and those for whom follow-
up is not envisaged or possible were excluded. To minimize
recruitment bias, investigator sites have been selected
randomly (apart from 18 sites, out of 1019) from all
participating countries, representing the actual care settings
in them assured by national coordinators. All eligible
patients were enrolled consecutively into 5 cohorts (repre-
senting the 5 years of enrollment); each cohort included
10 000 participants.20,21
Ethics Statement
Independent ethics committee and hospital-based institu-
tional review board approvals were obtained. The registry is
being conducted in accordance with the principles of the
Clinical Perspective
What Is New?
• The impact of increasing severity of chronic kidney disease
(CKD) on outcomes is well documented in studies con-
ducted in Western Europe and North America, but not the
rest of the world.
• The GARFIELD-AF (Global Anticoagulant Registry in the
FIELD–Atrial Fibrillation) registry shows that 1 year after
diagnosis of atrial ﬁbrillation, both mild and moderate-to-
severe CKD were independent risk factors for all-cause
mortality, after adjusting for baseline characteristics and
antithrombotic use.
• Moderate-to-severe CKD was also independently associated
with a higher risk of stroke/systemic embolism, major
bleeding, new-onset acute coronary syndrome, and new or
worsening heart failure; the impact of moderate-to-severe
CKD on mortality is even greater in patients from Asia,
where patient characteristics and the standard of care for
anticoagulation differs from the rest of the world.
What Are the Clinical Implications?
• Despite potential concerns over the lack of coagulation
monitoring with non–vitamin K antagonist oral anticoagu-
lants in patients with moderate-to-severe CKD, the data
from GARFIELD-AF suggest that the use of non–vitamin K
antagonist oral anticoagulants in these patients is similar to
their use in no/mild CKD in real-world clinical practice.
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Declaration of Helsinki, local regulatory requirements, and the
International Conference on Harmonisation–Good Pharma-
coepidemiological and Clinical Practice guidelines. Written
informed consent was obtained from all study participants.
Conﬁdentiality and anonymity of all patients recruited into this
registry are maintained.
Data Collection and Quality Control
Patient demographics, medical history, and the use of
antithrombotic treatment were recorded at baseline. Data
on components of the CHA2DS2-VASc
22 and HAS-BLED11 risk
stratiﬁcation schemes were collected to assess stroke and
bleeding risks retrospectively. HAS-BLED scores were calcu-
lated, excluding ﬂuctuations in international normalized ratio.
Incidences of stroke/systemic embolism (SE), major bleeding,
all-cause mortality, cardiovascular mortality, noncardiovascu-
lar mortality, undetermined cause of mortality, new diagnosis
of acute coronary syndrome (ACS), and new or worsening
(deﬁned by New York Heart Association class) heart failure
were recorded over 1-year follow-up.
The data were extracted from the study database on
November 2017, and includes patients prospectively recruited
between April 2013 and August 2016 (from cohorts 3–5).
Patients recruited before April 2013 were excluded because
of the lack of detailed information on the severity of CKD.
GARFIELD-AF data are captured using an electronic case
report form designed by Dendrite Clinical Systems Ltd
(Henley-on-Thames, United Kingdom). Oversight of operations
and data management are performed by the sponsor and
coordinating center (Thrombosis Research Institute—TRI,
London, United Kingdom), with support from Quintiles
(Durham, NC, United States), The University of Birmingham
Department of Primary Care Clinical Sciences (Birmingham,
United Kingdom), Thrombosis Research Group—Brigham and
Women’s Hospital (Boston, MA, United States), and AIXIAL
(Paris, France). Data management and quality assurance of
the database were controlled by an independent Audit
Committee (Prof. Keith Fox and Prof. Bernard Gersh). Details
of the quality assurance process in GARFIELD-AF have been
described previously.23
Study End Points
Outcome measures analyzed included all-cause mortality,
cardiovascular and noncardiovascular mortality, stroke/SE,
major bleeding, pulmonary embolism, heart failure (new or
worsening), and new-onset ACS.20 In this analysis, event rates
were analyzed only over the ﬁrst 12 months from diagnosis of
AF (to avoid the inﬂuence of time-dependent changes in CKD
stage) and only in the last 3 cohorts of patients recruited into
GARFIELD-AF to maintain the homogeneity within the use of
oral anticoagulants.
Deﬁnitions
Patients with AF diagnosed within the previous 6 weeks were
categorizedby the investigator as havingnew-onset (unclassiﬁed),
paroxysmal, persistent, or permanent AF. The severity of CKDwas
classiﬁed by the investigator according to the National Kidney
Foundation’s Kidney Disease Outcomes Quality Initiative guide-
lines.24 Guidance on CKD classiﬁcation was provided online for
investigators. Laboratory data on renal function were not
collected. Vascular disease included peripheral artery disease or
coronary artery disease (CAD) with a history of ACS. Asian
countries in this analysis were China, India, Japan, Singapore,
South Korea, and Thailand. Non-Asian countries included
Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech
Republic, Denmark, Egypt, Finland, France, Germany, Hungary,
Italy, Netherlands, Norway, Mexico, Poland, Russia, South Africa,
Spain, Sweden,Switzerland, Turkey, theUnitedKingdom,Ukraine,
the United Arab Emirates, and the United States.
Statistical Analysis
Patients were analyzed according to their severity of CKD,
either moderate-to-severe CKD (stages 3–5), mild CKD
(stages 1–2), or no CKD, as recorded by the phyisican. A
global analysis was conducted on data from all countries in
GARFIELD-AF, and then a regional comparison was made to
conﬁrm the validity of global results in patients enrolled
outside Asia and within Asia where the standard of antithrom-
botic therapy differs substantially.12
For the analysis of baseline parameters, continuous
variables are expressed as median (interquartile range) and
categorical variables as frequency and percentage.
The prevalence of comorbidities at baseline is shown by
the CKD group in the global and regional analyses. Antithrom-
botic treatment patterns at baseline are displayed by CKD
group and CHA2DS2-VASc score.
Clinical outcomes were compared between moderate-to-
severe CKD versus no CKD and mild CKD versus no CKD
groups. Occurrence of adverse clinical outcomes is described
using the number (%) of events, person-time event rate (per
100 person-years), and 95% CI. We estimated person-year
rates using a Poisson model, with the number of events as the
dependent variable and the log of person-time as an offset.
Only the ﬁrst occurrence of each event was used.
For patients treated with VKAs, the quality of anticoagu-
lation was assessed by comparing the time in therapeutic
range between moderate-to-severe CKD versus no CKD and
mild CKD versus no CKD groups using methods previously
described.25,26
Cox proportional hazard regression modeling was used to
determine the effects of moderate-to-severe and mild CKD
relative to no CKD on clinical outcomes up to 1 year after AF
diagnosis. Models were adjusted for the following a priori
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speciﬁed variables: age, sex, race, smoking, diabetes mellitus,
hypertension, previous stroke/transient ischemic attack/SE,
history of bleeding, heart failure, vascular disease, ACS,
anticoagulant and/or antiplatelet treatment, type of AF, and
heavy alcohol consumption.27
Five imputation data sets were generated using a multiple
imputation procedure,16,28,29 assuming arbitrary missing
patterns and applying a fully conditional speciﬁcation method
that assumes a joint distribution for all of the variables. The
fully conditional speciﬁcation method involves 2 steps. The
ﬁlled-in phase, where a discriminant function is used for
binary variables, logistic for ordinal, and regression for
continuous variables, ﬁlls in sequentially over the variables,
one at a time. In the imputation phase, these steps are
iterated to obtain ﬁnal estimates. Hazard ratios with 95% CIs
were calculated across the 5 imputed data sets, using
parameter estimates as well as the within- and between–data
set covariance matrices. The analyses were performed using
SAS version 9.4 (SAS Institute Inc., Cary, NC).
Results
Study Population
A total of 34 854 patients were enrolled in GARFIELD-AF from
1119 sites in 35 countries between April 2013 and August
2016. Of these, 1830 with unknown/missing data for CKD
stage at baseline were excluded and 33 024 analyzed. Globally,
physicians classiﬁed 10.9% of patients withmoderate-to-severe
CKD (stage 3, n=3049; stage 4, n=397; stage 5, n=167), 16.9%
with mild CKD (stage 1, n=1984; stage 2, n=3611), and 72.1%
with no CKD (n=23 816). Baseline demographics, clinical
characteristics, and care settings for each CKD group are
shown in Figure 1 and Table 1. Compared with patients with
mild or no CKD at the time of diagnosis of AF, patients with
moderate-to-severe CKD were older (78.0 years versus
69.0 years without CKD) and were more likely to be female.
In GARFIELD-AF, the detection of moderate-to-severe CKD
stagewas less likely (thanmild or noCKD) in patients of Chinese
and Hispanic/Latino ethnicity. As shown in Figure 1, comorbid
heart failure, previous history of CAD, carotid occlusive disease,
coronary artery bypass surgery, stroke and/or transient
ischemic attack, pulmonary embolism, deep vein thrombosis,
bleeding, and diabetesmellitus tended to occurmore frequently
in advanced CKD. Overall, patients with moderate-to-severe
CKD had a numerically higher median CHA2DS2-VASc score of
4.0 as compared with a score of 3.0 in patients with mild or no
CKD. Similarly, a numerically higher HAS-BLED score of 2.0 was
observed for patients with moderate-to-severe CKD and 1.0 for
patients with mild and no CKD (Table 1).
In total, 9491 of 33 024 patients (28.7%) were recruited
from countries in Asia (China, India, Japan, Singapore, South
Figure 1. Prevalence of comorbidities according to chronic kidney disease group. Carotid occlusive disease (missing n=549); CABG (missing
n=72); PE/DVT (missing n=172); systemic embolism (missing=174); history of bleeding (missing n=125). CABG indicates coronary artery bypass
graft; CAD, coronary artery disease; CHF, congestive heart failure; CKD indicates chronic kidney disease; DVT, deep vein thrombosis; PE,
pulmonary embolism; TIA, transient ischemic attack.
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Table 1. Demographics, Clinical Characteristics and Care Settings of Patients According to CKD Group
Variable Moderate-to-Severe CKD (n=3613) Mild CKD (n=5595) No CKD (n=23 816)
Female, n (%) 1828 (50.6) 2423 (43.3) 10 386 (43.6)
Age at AF diagnosis (y), median (IQR) 78.0 (71.0–83.0) 71.0 (63.0–78.0) 69.0 (61.0–77.0)
Race, n/n patients in each ethnic group (%)
White 2491 (68.9) 3864 (69.1) 13 553 (56.9)
Hispanic/Latino 134 (3.7) 202 (3.6) 1543 (6.5)
Afro-Caribbean 25 (0.7) 30 (0.5) 141 (0.6)
Asian (not Chinese) 750 (20.8) 998 (17.8) 6455 (27.1)
Chinese 83 (2.3) 260 (4.6) 1356 (5.7)
Mixed/other 39 (1.1) 62 (1.1) 400 (1.7)
Unwilling to declare/not known 91 (2.5) 179 (3.2) 368 (1.5)
BMI, kg/m²
Median (IQR) 27.0 (24.0–31.0) 27.0 (24.0–31.0) 27.0 (24.0–31.0)
BMI category, n/n (%)
<19 95 (3.3) 124 (2.8) 488 (2.7)
19 to <25 943 (33.1) 1299 (28.9) 5835 (32.0)
25 to <30 966 (33.9) 1691 (37.6) 6759 (37.1)
30 to <40 762 (26.7) 1190 (26.5) 4509 (24.8)
≥40 85 (3.0) 195 (4.3) 627 (3.4)
Missing 762 (21.1%) 1096 (19.6%) 5598 (23.5%)
Alcohol consumption, n (%)
Abstinent 1767 (58.1) 2385 (48.6) 11 530 (57.6)
Light 1006 (33.1) 1862 (37.9) 6078 (30.4)
Moderate 219 (7.2) 528 (10.8) 1973 (9.9)
Heavy 51 (1.7) 133 (2.7) 435 (2.2)
Missing 570 (15.8%) 687 (12.3%) 3800 (16.0%)
Smoking, n (%)
Nonsmoker 2158 (64.9) 3225 (61.2) 14 506 (66.7)
Ex-smoker 975 (29.3) 1461 (27.7) 4691 (21.6)
Current smoker 190 (5.7) 584 (11.1) 2551 (11.7)
Missing 290 (8.0%) 325 (5.8%) 2068 (8.7%)
Type of AF, n (%)
New onset (unclassified) 1632 (45.2) 2703 (48.3) 10 062 (42.2)
Paroxysmal 892 (24.7) 1405 (25.1) 7270 (30.5)
Persistent 533 (14.8) 729 (13.0) 3536 (14.8)
Permanent 556 (15.4) 758 (13.5) 2948 (12.4)
CHA2DS2-VASc score, median (IQR) 4.0 (3.0–5.0) 3.0 (2.0–4.0) 3.0 (2.0–4.0)
Missing 74 (2.0%) 127 (2.3%) 680 (2.9%)
HAS-BLED score, median (IQR) 2.0 (2.0–3.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Missing 741 (20.5%) 909 (16.2%) 4699 (19.7%)
Antithrombotic treatment, n (%)
VKAantiplatelet 1421 (40.0) 2117 (38.4) 7515 (31.9)
NOACantiplatelet 1194 (33.5) 1942 (35.3) 8752 (37.2)
Continued
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Korea, and Thailand), including 774 patients with moderate-to-
severe CKD. The clinical characteristic and antithrombotic
treatment of patients recruited from Asian and non-Asian
countries, stratiﬁed by CKD group, are reported in Table S1. The
analyses show that patients from Asia and the RoW have a
similar stroke risk (as deﬁned by CHA2DS2-VASc). Compared
with patients with mild or no CKD, patients with moderate-to-
severe CKD from Asian and non-Asian countries tended to be
older and have a higher prevalence of heart failure, CAD,
hypercholesterolemia, history of hypertension, vascular dis-
ease, and diabetes mellitus. However, patients from Asia
(relative to the patients from the RoW) tended to have a more
modest body mass index, and in Asian patients with mild or no
CKD, there was a lower prevalence of CAD, hypercholes-
terolemia, and hypertension.
Antithrombotic Therapy Use According to CKD
Group and Stroke Risk
Table 1 shows that slightly more patients with than without
CKD were anticoagulated (73.5% and 73.7% versus 69.1%,
respectively). The decision to use anticoagulants with or
without AP therapy was inﬂuenced primarily by CHA2DS2-
VASc score irrespective of CKD status (Figure 2A). For
patients with the same CHA2DS2-VASc score, the prescribing
of anticoagulants did not differ substantially between those
with moderate-to-severe, mild, and no CKD: 57.8%, 59.0%,
and 55.7% (for those with a CHA2DS2-VASc score of 0–1) and
74.5%, 77.1%, and 73.7% (for a CHA2DS2-VASc score of 3 or
more).
VKA prescribing tended to be slightly more frequent in
patients with CKD. For example, in patients with a CHA2DS2-
VASc score of ≥3, VKAantiplatelet use was 40.5% and
39.6% (for moderate-severe and mild CKD) and 35.0% (for no
CKD). With NOACs (factor Xa inhibitor or direct thrombin
inhibitor), the opposite trend was observed; although a
substantial of proportion of patients with moderate-to-severe
CKD received NOACs (34.0%) versus 37.5% (for mild CKD)
and 38.7% (for no CKD) in patients with a CHA2DS2-VASc
score of ≥3. The quality of anticoagulant control with VKAs,
as measured by time in therapeutic range, did not differ with
CKD stage (Table 1).
The use of antiplatelet therapy alone was similar
irrespective of CKD status. For example, in CHA2DS2-VASc
0–1 patients, antiplatelet use was 18.7%, 21.6%, and
20.6% for moderate-to-severe, mild, and no CKD, respec-
tively; in patients with a CHA2DS2-VASc score of ≥3,
antiplatelet use was 16.5%, 14.6%, and 17.0% of patients,
respectively. In contrast, the proportion of patients who
received no antithrombotic therapy (neither anticoagulant
nor antiplatelet) appeared to be inﬂuenced primarily by
stroke risk (based on the post hoc assessment of the
Table 1. Continued
Variable Moderate-to-Severe CKD (n=3613) Mild CKD (n=5595) No CKD (n=23 816)
Antiplatelet only 593 (16.7) 873 (15.8) 4190 (17.8)
No antithrombotic 350 (9.8) 580 (10.5) 3078 (13.1)
Missing 47 (1.3%) 68 (1.2%) 227 (1.0%)
ACS 561 (15.7%) 625 (11.2%) 1944 (8.2)
Missing 29 (0.8%) 18 (0.3%) 164 (0.7%)
Time in therapeutic range median (IQR) 50.0 (33.3–66.7) 50.0 (33.3–66.7) 50.0 (33.3–66.7)
Care setting specialty at diagnosis, n (%)
Cardiology 20 843 (57.7) 3430 (61.3) 16 858 (70.8)
Geriatrics 36 (1.0) 26 (0.5) 55 (0.2)
Internal medicine 758 (21.0) 1129 (20.2) 3763 (15.8)
Neurology 72 (2.0) 95/5595 (1.7) 317 (1.3)
Primary care/general practice 663 (18.4) 915 (16.4) 2823 (11.9)
Care setting location at diagnosis, n (%)
Anticoagulation clinic/thrombosis centre 14 (0.4) 30 (0.5) 79 (0.3)
Emergency room 351 (9.7) 669 (12.0) 2392 (10.0)
Hospital 2095 (58.0) 3412 (61.0) 13 320 (55.9)
Office 1153 (31.9) 1484 (26.5) 8025 (33.7)
Percentages in the table refer to complete data, except for the missing data percentages. ACS indicates acute coronary syndrome; AF, atrial ﬁbrillation; BMI, body mass index; CKD, chronic
kidney disease; IQR, interquartile range; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
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CHA2DS2-VASc score). For patients with a CHA2DS2-VASc
score of ≥3 versus those with a CHA2DS2-VASc score of
0–1, the proportion on no antithrombotic therapy was
9.0% versus 23.6% (for moderate-to-severe CKD), 8.4%
versus 19.5% (for mild CKD), and 9.3% versus 23.7% (for
no CKD).
Figure 2. Antithrombotic therapy at diagnosis according to chronic kidney disease (CKD) group
and CHA2DS2-VASc score (A) worldwide (B) Asian (C) non-Asian countries. AP indicates
antiplatelet; DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K antagonist.
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Antithrombotic Therapy Use in Asia Versus RoW
We observed that the standard of care with antithrombotic
therapy differed in Asia compared with the RoW. Although the
use of NOACs (factor Xa inhibitor and direct thrombin
inhibitor) antiplatelet was similar in both Asian and non-
Asian countries (Table S1) when CHA2DS2-VASc was ≤1,
NOAC use was lower in Asian countries (Figure 2B and 2C).
Overall, VKAantiplatelet was more commonly prescribed
outside Asia (Table S1). Antiplatelet therapy as a lone therapy
for stroke prevention was more likely to be used in Asia than
elsewhere (Figure 2B and 2C; Table S1).
Clinical Outcomes
Relative to patients with no CKD, unadjusted rates of stroke/
SE 1 year after the diagnosis of AF were twice as high in
patients with moderate-to-severe CKD (Table 2). For all-cause
mortality and major bleeding, event rates were 3-fold higher
(Table 2). The most frequent known causes of death in
patients with moderate-to-severe CKD were heart failure and
infection/sepsis, and in patients with mild CKD or no CKD,
heart failure and malignancy (Table S2). In all CKD groups,
primary ischemic strokes were more frequent than primary
intracerebral hemorrhages. Nonmajor clinically relevant
bleeds were more common than major bleeds across all
CKD groups. Fatal bleeding was rare across CKD stages,
accounting for 7%, 5%, and 8% of all bleeding events in the
moderate-to-severe CKD, mild CKD, and no CKD groups,
respectively.
After adjusting for baseline characteristics and antithrom-
botic use, hazard ratios showed that moderate-to-severe
CKD was an independent risk factor for stroke/SE, major
bleeding, all-cause mortality, cardiovascular/noncardiovascular
mortality, new onset of ACS, and heart failure within 1 year of
the diagnosis of AF (Figure 3). Differences in mortality were
statistically signiﬁcant for comparisons of moderate-to-severe
versus no CKD and for mild CKD versus no CKD. Differences in
stroke/SE events and major bleed were statistically signiﬁcant
for the comparison of moderate-to-severe CKD versus no CKD,
but not for mild CKD versus no CKD during the 1 year after the
diagnosis of AF (Figure 3).
The interaction of CKD with age, race, and sex was
evaluated for each of the primary end points (mortality,
stroke/SE, and major bleeding). The only interaction that was
statistically signiﬁcant was the interaction between age and
CKD for all-cause mortality (P<0.001). Relative to patients
with no CKD, the hazard ratios for all-cause mortality were
numerically greater in younger than older patients with CKD
(either mild or moderate-to-severe CKD).
Comparison Between Patients Recruited From
Asian and Non-Asian Countries
Table 3 describes the unadjusted event rates (per 100 per-
son-years) over 1 year in patients from Asia and the RoW. Our
ﬁndings show that mortality rates in patients with mild or no
CKD are substantially lower in patients from Asia than
elsewhere. Moderate-to-severe CKD, however, is associated
with high mortality rates regardless of region. Relative to
patients with no CKD, the impact of moderate-to-severe CKD
on mortality was greater in patients from Asia than the RoW
(P=0.002), and this difference remained signiﬁcant after
adjustment for treatment and baseline risk factors (Figure 4;
P=0.001). In countries outside Asia, mild CKD was also
associated with an elevated risk of mortality (which is not
observed in Asia) even after adjustment for treatment and
baseline risk factors (Figure 4).
Table 2. Events Rates Per 100 Person-Years During 1-Year Follow-Up According to CKD Group
Moderate-to-Severe CKD (n=3613) Mild CKD (n=5595) No CKD (n=23 816)
n (%)
Rate, Per 100 Person-
Years (95% CI) n (%)
Rate, Per 100 Person-
Years (95% CI) n (%)
Rate, Per 100 Person-
Years (95% CI)
Stroke/SE 74 (2.0) 2.25 (1.79–2.82) 64 (1.1) 1.21 (0.95–1.55) 233 (1.0) 1.03 (0.91–1.18)
Major bleeding 61 (1.7) 1.85 (1.44–2.38) 52 (0.9) 0.98 (0.75–1.29) 143 (0.6) 0.63 (0.54–0.75)
All-cause mortality 344 (9.5) 10.35 (9.31–11.51) 297 (5.3) 5. 60 (4.99–6.27) 729 (3.1) 3.22 (3.00–3.46)
Cardiovascular mortality 148 (4.1) 4.45 (3.79–5.23) 102 (1.8) 1.92 (1.58–2.33) 227 (1.0) 1.00 (0.88–1.14)
Noncardiovascular mortality 125 (3.5) 3.76 (3.16–4.48) 106 (1.9) 2.00 (1.65–2.42) 292 (1.2) 1.29 (1.15–1.45)
Undetermined cause
of mortality
71 (2.0) 2.14 (1.69–2.70) 89 (1.6) 1.68 (1.36–2.06) 210 (0.9) 0.93 (0.81–1.06)
New ACS 51 (1.4) 1.55 (1.17–2.03) 36 (0.6) 0.68 (0.49–0.94) 133 (0.6) 0.59 (0.50–0.70)
New congestive heart failure 104 (2.9) 3.19 (2.63–3.86) 90 (1.6) 1.71 (1.39–2.10) 284 (1.2) 1.27 (1.13–1.42)
ACS indicates acute coronary syndrome; CKD, chronic kidney disease; SE, systemic embolism.
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Although we observed a trend toward a lower rate of major
bleeds, new ACS, and new or worsening heart failure in
patients from Asia compared with the RoW (Table 3), the
number of events was too low to compare the impact of CKD
severity on these outcomes by region using adjusted analyses.
Discussion
We found that both mild and moderate-to-severe CKD are
independently associated with all-cause mortality in patients
with a new diagnosis of AF. Moderate-to-severe CKD was also
independently associated with a higher risk of stroke/SE,
major bleeding, new-onset ACS, and new or worsening heart
failure. The impact of moderate-to-severe CKD on mortality is
even greater while that of mild CKD was less in patients from
Asia, where patient characteristics and the standard of care
for anticoagulation differs from the RoW.
A substantial proportion of patients (27.8%) with newly
diagnosed AF in GARFIELD-AF had comorbid CKD. Patients
with moderate-to-severe CKD tended to be older and,
therefore, were more likely to have higher CHA2DS2-VASc
and HAS-BLED scores in the global and regional analyses.
They also had a higher prevalence of comorbidities, including
heart failure, CAD, history of coronary artery bypass graft,
hypertension, stroke/ transient ischemic attack, or bleeding;
vascular disease; and diabetes mellitus. The ﬁnding that
moderate-to-severe CKD increased all-cause mortality was a
consistent ﬁnding in the global analyses as well as in the
regional analyses of Asian and non-Asian countries. However,
the increased risk of mortality with mild CKD was observed
only in patients outside Asia. This latter ﬁnding may reﬂect a
lower prevalence of CAD, hypercholesterolemia, and hyper-
tension in Asian patients compared with RoW.
Rates of stroke/SE, major bleeding, cardiovascular mor-
tality, noncardiovascular mortality, new onset of ACS, and
heart failure were higher in patients with moderate-to-severe
CKD than in patients with no CKD (globally and regionally).
These differences persisted after adjustment in the global
assessment, suggesting the robustness of our ﬁndings. These
ﬁndings are consistent with our previously published analyses
of the whole GARFIELD-AF cohort, which identiﬁed a greater
proportion of low-stroke-risk patients in Asia than the RoW.30
Although few patients were recruited from the United States
(n=732, 2.1%) into GARFIELD-AF, the higher bleeding events
in moderate-to-severe CKD patients globally were consistent
with results observed by O’Brien et al (2015) in the US
Figure 3. Adjusted hazard ratios for 1-year clinical outcomes according to severity of chronic kidney
disease. Hazard ratios were adjusted for age, sex, race, smoking, diabetes mellitus, hypertension, previous
stroke/transient ischemic attack/systemic embolism, history of bleeding, heart failure, vascular disease,
acute coronary syndrome, anticoagulant treatment, type of atrial ﬁbrillation, and alcohol consumption. ACS
indicates acute coronary syndromes; aHR, adjusted hazard ratio; CKD, chronic kidney disease; SE, systemic
embolism.
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registry, ORBIT-AF (Outcomes Registry for Better Informed
Treatment of Atrial Fibrillation).31
Compared with patients with no CKD, patients with
moderate-to-severe or mild CKD had a higher cardiovascular
mortality rate in the global analyses. Heart failure was the
most common cause of death, amounting to 47% (70 of 148)
cardiovascular deaths; sudden/unwitnessed deaths and
deaths from ACS were relatively rare; and ischemic stroke
accounted for only 3% of all-cause mortality in patients with
moderate-to-severe CKD. Of the noncardiac causes of death,
malignancy was more common in patients with no or mild
CKD than in patients with moderate-to-severe CKD, while
infection/sepsis was more frequent in patients with moder-
ate-to-severe CKD. Fatal bleeding was rare across CKD
stages, accounting for 7%, 5%, and 8% of all bleeding events in
the moderate-to-severe CKD, mild CKD, and no CKD groups,
respectively.
More than 30% of patients were on NOACs, irrespective of
their CKD stage when CHA2DS2-VASc score was ≥2. Because
all NOACs are excreted, at least in part, from the kidney, and
dabigatran is contraindicated in severe renal failure, the
similar frequency of NOAC use in mild and moderate-to-
severe CKD in the real-world GARFIELD-AF registry is
noteworthy. The primary consideration of physicians when
prescribing any anticoagulant (either VKA or NOAC) in
patients with moderate-to-severe CKD and mild CKD appears
to be the patients’ stroke risk, represented by the post hoc
assessment of CHA2DS2-VASc score, with higher overall
frequency of anticoagulant use in patients with the highest
stroke risk. VKAs tended to be prescribed more frequently
than NOACs (factor Xa inhibitor and direct thrombin inhibitor)
in patients with moderate-to-severe CKD.
Clinical Perspectives
Recent publications have demonstrated the limitation of the
CHA2DS2-VASc score for predicting future strokes in patients
with AF.32 Of the potential risk factors omitted in the
CHA2DS2-VASc score, renal dysfunction is highlighted by
many clinical studies.9,33–35 There are, however, studies that
suggest that the predictive value of the CHA2DS2-VASc score
is not improved by addition of CKD status because the factors
within CHA2DS2-VASc are themselves related to renal
dysfunction.36 Indeed, a previous systematic review reassured
Table 3. Event Rates Per 100 Person-Years During 1-Year Follow-Up in Patients Stratiﬁed by Region (Asia and Rest of World) and
CKD Group
Variable Statistics
According to CKD Severity
Asia* Rest of World
Moderate to Severe
(N=774) Mild (N=1225) None (N=7492)
Moderate to Severe
(N=2839) Mild (N=4370) None (N=16 324)
All-cause
mortality
n (%) 66 (8.5) 29 (2.4) 167 (2.2) 278 (9.8) 268 (6.1) 562 (3.4)
Rate (95% CI) 9.33 (7.33, 11.87) 2.45 (1.70, 3.53) 2.38 (2.05, 2.77) 10.63 (9.45, 11.96) 6.50 (5.76, 7.32) 3.60 (3.31, 3.91)
Cardiovascular
mortality
n (%) 23 (3.0) 6 (0.5) 48 (0.6) 125 (4.4) 96 (2.2) 179 (1.1)




n (%) 26 (3.4) 18 (1.5) 53 (0.7) 99 (3.5) 88 (2.0) 239 (1.5)




n (%) 17 (2.2) 5 (0.4) 66 (0.9) 54 (1.9) 84 (1.9) 144 (0.9)
Rate (95% CI) 2.40 (1.49–3.86) 0.42 (0.18–1.02) 0.94 (0.74–1.20) 2.07 (1.58–2.70) 2.04 (1.64–2.52) 0.92 (0.78–1.09)
Stroke/SE n (%) 13 (1.7) 14 (1.1) 67 (0.9) 61 (2.1) 50 (1.1) 166 (1.0)
Rate (95% CI) 1.85 (1.07–3.18) 1.19 (0.71–2.01) 0.96 (0.76–1.22) 2.35 (1.83, 3.02) 1.22 (0.92–1.61) 1.07 (0.92–1.24)
Major bleed n (%) 11 (1.4) 9 (0.7) 19 (0.3) 50 (1.8) 43 (1.0) 124 (0.8)
Rate (95% CI) 1.56 (0.87–2.82) 0.77 (0.40–1.47) 0.27 (0.17–0.43) 1.93 (1.46–2.54) 1.05 (0.78–1.41) 0.80 (0.67–0.95)
New ACS n (%) 8 (1.0) 13 (0.2) 43 (1.5) 36 (0.8) 120 (0.7)




n (%) 9 (1.2) 6 (0.5) 61 (0.8) 95 (3.3) 84 (1.9) 223 (1.4)
Rate (95% CI) 1.28 (0.67–2.46) 0.51 (0.23–1.13) 0.88 (0.68–1.13) 3.71 (3.04–4.54) 2.06 (1.66–2.55) 1.44 (1.26–1.64)
ACS indicates acute coronary syndrome; CKD, chronic kidney disease; SE, systemic embolism.
*Asia includes China, India, Japan, Singapore, South Korea, and Thailand.
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that only the original components of the CHA2DS2-VASc score
were independently predictive for stroke in AF.37 Our data
conﬁrm higher stroke/SE, cardiovascular/noncardiovascu-
lar/undetermined mortality, other vascular events, and heart
failure in AF patients with concomitant moderate-to-severe
CKD. An important distinction between our study and
previously published studies is that our study is not focused
just on stroke. The presence of CKD is strongly associated
with an increased risk of mortality.
Despite potential concerns over the lack of coagulation
monitoring with NOACs in patients with moderate-to-severe
CKD,38 our data suggest that the use of NOACs in these
patients is similar to the use in no/mild CKD in real-world
clinical practice. This may reﬂect the difﬁculties in prescribing
VKAs to patients with CKD, which have been observed in both
the clinical trial setting and observational studies (outside
specialist centers).5,39
Limitations
GARFIELD-AF is an observational prospective registry and not
a randomized trial. Though adjustments were made for the
parameters known to inﬂuence clinical outcomes, the differ-
ences between no CKD and (mild or moderate-to-severe) CKD
may still be inﬂuenced by unknown confounder(s).
Our analyses focus on 1-year outcomes to avoid the
inﬂuence of the time-dependent change in CKD stage. But
CKD stage was assessed only at the time of enrollment. There
may be some patients whose kidney function deteriorated
rapidly even within this 1-year period.
Moreover, the CKD stage was based on the investigators’
judgment, according to the National Kidney Foundation’s
Kidney Disease Outcomes Quality Initiative guidelines,24 rather
than by the collection of laboratory data in the case report form.
We also acknowledge that there is wide heterogeneity
within the Asian population in the GARFIELD-AF registry.
Despite this heterogeneity, we have previously shown that
patients from Asia (including the Asia-Paciﬁc region as well
as China and India) have a lower stroke risk than patients
from outside Asia.30 When testing the internal validity of our
global ﬁndings, we compared the impact of CKD in patients
from Asia and outside Asian using the same regional
deﬁnitions as described in our previous analyses.30 However,
due to the small number of patients of Asian origin outside
Asia, we were not able to distinguish between the impact of
race and impact of region for Asians in this study.
It is also noteworthy that not all regions are equally
represented in GARFIELD-AF. For example, a relatively low
number of patients were recruited from the United States.
However, in a collaboration with the US registry, ORBIT-AF, we
Figure 4. Adjusted hazard ratios for 1-year clinical outcomes according to severity of chronic kidney
disease (CKD) in Asia and non-Asian countries. Hazard ratios were adjusted for age, sex, race, smoking,
diabetes mellitus, hypertension, previous stroke/transient ischemic attack/systemic embolism, history of
bleeding, heart failure, vascular disease, acute coronary syndrome, anticoagulant treatment, type of atrial
ﬁbrillation, and alcohol consumption. aHR indicates adjusted hazard ratio; SE, systemic embolism.
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have previously published data on the baseline characteristics
of patients and stroke prevention strategies of both reg-
istries.40 To date, however, the data from these 2 contem-
porary registries in AF have not been merged.
To avoid channeling bias,41 GARFIELD-AF was designed as
a noninterventional study—so that no tests, visits, or
treatments were prespeciﬁed in the protocol and the decision
to use or not use antithrombotic agents was solely at the
discretion of the investigator. However, in the context of CKD,
it is likely that physicians may, or may not, have modiﬁed the
dose of NOAC according to renal function.42–47 We recognize
that inappropriate dosing of NOACs in CKD patients might be
another factor related to worse clinical outcomes. This will be
the subject of a future study.
Conclusions
Our results show that, even after adjustment for the higher
rates of comorbidities, renal dysfunction deﬁned as moderate-
to-severe CKD is independently associated with higher risks
of stroke/SE, major bleeding, all-cause mortality, and various
cardiovascular events. The impact of moderate-to-severe CKD
on mortality varies in different regions of the world. Greater
impact was shown in patients from Asia than elsewhere. Use
of anticoagulants, including NOACs, is inﬂuenced primarily by
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Table S1. Patient characteristics, antithrombotic treatment, and time in therapeutic range by region and chronic kidney disease severity. 
 









Age, years, median (IQR) 76.0 (68.0 to 82.0) 69.0 (60.0 to 76.0) 78.0 (72.0 to 83.0) 70.0 (62.0 to 77.0) 
BMI, kg/m², median (IQR) 24.0 (21.0 to 26.0) 24.0 (22.0 to 27.0) 28.0 (25.0 to 32.0) 28.0 (25.0 to 32.0) 
Congestive heart failure, n (%) 243 (31.4) 1618 (18.6) 818 (28.8) 3766 (18.2) 
Coronary artery disease, n (%) 160 (20.7) 1462 (16.8) 927 (32.7) 4783 (23.1) 
Hypercholesterolaemia, n*** (%) 304 (40.9) 2457 (28.7) 1456 (53.1) 9167 (46.5) 
History of hypertension, n (%) 617 (79.8) 5778 (66.5) 2401 (84.7) 16,007 (77.6) 
Diabetes mellitus, n (%) 229 (29.6) 1803 (20.7) 853 (30.0) 4478 (21.6) 
CHA2DS2-VASc score, median (IQR) 4.0 (3.0 to 5.0)† 3.0 (2.0 to 4.0)‡ 4.0 (3.0 to 5.0)§ 3.0 (2.0 to 4.0)|| 
HAS-BLED score, median (IQR) 2.0 (2.0 to 3.0)# 1.0 (1.0 to 2.0)** 2.0 (2.0 to 3.0)†† 1.0 (1.0 to 2.0)‡‡ 
Care setting at diagnosis, n (%)     
    Cardiology 575 (74.3) 7340 (84.2) 1509 (53.2) 12,948 (62.6) 
    Geriatrics 2 (0.3) 16 (0.2) 34 (1.2) 65 (0.3) 
  
 









    Internal medicine 156 (20.2) 1040 (11.9) 602 (21.2) 3852 (18.6) 
    Neurology 15 (1.9) 73 (0.8) 57 (2.0) 339 (1.6) 
    Primary care/general practice 26 (3.4) 248 (2.8) 637 (22.4) 3490 (16.9) 
VKA ± antiplatelet, n (%) 249 (32.3) 2279 (26.2) 1172 (42.1) 7353 (36.1) 
       TTR ≥65% (target INR of 2.0–3.0), 
n (%) 
23 (16.0) 214 (19.8) 318 (44.4) 1911 (46.3) 
     TTR ≥65% (target INR of 1.6–2.6), n 
(%) 
34 (23.6) 272 (25.1) 318 (44.4) 1911 (46.3) 
NOAC ± antiplatelet, n (%) 256 (33.0) 2917 (33.5) 946  (33.7) 7846 (38.2) 
Antiplatelet only, n (%) 169 (21.9) 2024 (23.3) 424 (15.2) 3039 (14.9) 
No antithrombotic, n (%) 99 (12.8) 1473 (16.9.0) 251 (9.0) 2185 (10.7) 
VKA ± antiplatelet, n (%) 249 (32.2) 2279 (26.2) 1172 (42.0) 7353 (36.0) 
*Asia includes China, India, Japan, Singapore, South Korea, and Thailand. †14 patients missing; ‡183 patients missing; §60 patients missing; ||624 patients missing; #154 
patients missing; **1625 patients missing; ††587 patients missing; ‡‡3983 patients missing ***  287 patients missing. BMI, body mass index; CKD, chronic kidney disease; 
INR, international normalized ratio; IQR, interquartile range; NOAC, non-vitamin K antagonist oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K antagonist. 
  
Table S2. First events during 1-year follow-up according to chronic kidney disease severity. 







All-cause mortality 334 297 729 
    Cardiovascular causes 148 (43.0) 102 (34.3) 227 (31.1) 
      Heart failure 70 (20.3) 29 (9.8) 78 (10.7) 
     Sudden death 19 (5.5) 26 (8.8) 24 (3.3) 
     ACS 14 (4.1) 7 (2.4) 28 (3.8) 
     Ischaemic stroke 9 (2.6) 13 (4.4) 30 (4.1) 
     Other‡ 36 (10.5) 27 (9.1) 67 (9.2) 
    Non-cardiovascular causes 125 (36.3) 106 (35.7) 292 (40.1) 
            Malignancy 21 (6.1) 40 (13.5) 101 (13.9) 
            Respiratory failure 16 (4.7) 17 (5.7) 50 (6.9) 
            Infection/sepsis 41 (11.9) 24 (8.1) 57 (7.8) 
            Suicide 1 (0.3) - 3 (0.4) 
            Other§ 46 (13.4) 25 (8.4) 81 (11.1) 
    Undetermined causes 71 (20.6) 89 (30.0) 210 (28.8) 
Stroke (not including SE)* 66 58 214 
    Primary ischaemic stroke 45 (68.2) 40 (69.0) 154 (72.0) 
     Of which secondary   
haemorrhagic ischaemic 
stroke 
2 (3.0) 7 (12.1) 8 (3.7) 
    Primary intracerebral 
haemorrhage 
8 (12.1) 5 (8.6) 29 (13.6) 
  
            Intracerebral 6 (9.1) 1 (1.7) 21 (9.8) 
            Subarachnoid 1 (1.5) 3 (5.2) 5 (2.3) 
            Intraventricular - 2 (3.5) 3 (1.4) 
            Subdural Haematoma - - 1 (0.5) 
    Undetermined† 13 (19.7) 13 (22.4) 31 (14.5) 
Bleeding events (not 
including minor bleeds)* 
150 139 373 
    Severity of bleed    
            Non-major clinically 
relevant 
89 (59.3) 87 (62.6) 230 (61.7) 
            Major 61 (40.7) 52 (37.4) 143 (38.3) 
    Fatal 10 (6.7) 7 (5.0) 29 (7.8) 
*Only the first occurrence was taken into account. 
†Includes patients with either undetermined or unknown types of stroke and those with both 
primary ischaemic and primary intracerebral haemorrhagic strokes.                                                                
   ‡Includes deaths due to intracranial haemorrhage, atherosclerotic vascular disease, dysrhythmia, 
pulmonary embolism, and haemorrhagic stroke. §Includes deaths due to accidents/trauma, renal 
disease, and liver disease. 
ACS, acute coronary syndromes; CKD, chronic kidney disease; SE, systemic embolism 
 
  
